In vitro epithelial models comprising lamina propria-derived cells

US11059041B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11059041-B2
Application numberUS-202017024221-A
CountryUS
Kind codeB2
Filing dateSep 17, 2020
Priority dateDec 2, 2016
Publication dateJul 13, 2021
Grant dateJul 13, 2021

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

An in vitro microfluidic “organ-on-chip” is described herein that mimics the structure and at least one function of specific areas of the epithelial system in vivo. In particular, a multicellular, layered, microfluidic culture is described, allowing for interactions between lamina propria-derived cells and the associated tissue specific epithelial cells and endothelial cells. This in vitro microfluidic system can be used for modeling inflammatory tissue, e.g., autoimmune disorders involving epithelia and diseases involving epithelial layers. These multicellular, layered microfluidic “organ-on-chip”, e.g. “epithelia-on-chip” further allow for comparisons between types of epithelia tissues, e.g., lung (Lung-On-Chip), bronchial (Airway-On-Chip), skin (Skin-On-Chip), cervix (Cervix-On-Chip), blood brain barrier (BBB-On-Chip), etc., in additional to neurovascular tissue, (Brain-On-Chip), and between different disease states of tissue, i.e. healthy, pre-disease and diseased areas. Additionally, these microfluidic “organ-on-chips” allow identification of cells and cellular derived factors driving disease states in addition to drug testing for reducing inflammation effecting epithelial regions.

First claim

Opening claim text (preview).

What is claimed is: 1. A microfluidic device comprising: a) a first microfluidic channel in fluidic communication with a second microfluidic channel, with a semi-permeable membrane disposed between said first and second microfluidic channels, b) first cells comprising at least one parenchymal cell type, said first cells are disposed in said first channel; and c) second cells comprising at least one stromal cell type, wherein said stromal cell type is a lamina propria-derived cell, said second cells are disposed in said first channel or in said second channel. 2. The microfluidic device of claim 1 , wherein said parenchymal cell type is selected from the group consisting of epithelial cells of the lung, epithelial cells of the skin and epithelial cells of the urogenital tract. 3. The microfluidic device of claim 2 , wherein said epithelial cells of the lung are selected from the group consisting of alveolar epithelial cells and airway epithelial cells. 4. The microfluidic device of claim 1 , wherein at least one of said first cells and second cells comprise cells derived from a tumor. 5. The microfluidic device of claim 1 , wherein at least one of said first cells and second cells comprise cells derived from a region in or around a tumor. 6. The microfluidic device of claim 1 , wherein at least one of said first cells and second cells comprise cells from a region of inflammation. 7. The microfluidic device of claim 1 , wherein at least a portion of said second cells are disposed in contact with said semi-permeable membrane. 8. The microfluidic device of claim 1 , wherein the device further comprises a gel disposed in said first channel or in said second channel. 9. The microfluidic device of claim 8 , wherein at least a portion of said second cells are disposed within said gel. 10. The microfluidic device of claim 1 , further comprising a removable top. 11. The microfluidic device of claim 1 , further comprising a removable top that defines an open region in contact with at least one of said first fluidic channel, said semi-permeable membrane, said first cells, or said second cells. 12. The microfluidic device of claim 1 , wherein said lamina propria-derived cell is viable after culture for 2 weeks in said microfluidic device. 13. The microfluidic device of claim 1 , wherein said parenchymal cell type expresses a higher level of parenchymal cell marker in the presence of said lamina propria-derived cell than in the absence of said of said lamina propria-derived cell.

Assignees

Inventors

Classifications

  • involving specific cell types · CPC title

  • characterised by interfacing components, e.g. fluidic, electrical, optical or mechanical interfaces · CPC title

  • C12M23/16Primary

    Microfluidic devices; Capillary tubes (integrated microfluidic structures B01L3/5027; microreactors B01J19/0093) · CPC title

  • Culture media for cell or tissue culture (media for specific animal cell type C12N5/06) · CPC title

  • Chemical, biochemical or biological means, e.g. plasma jet, co-culture · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11059041B2 cover?
An in vitro microfluidic “organ-on-chip” is described herein that mimics the structure and at least one function of specific areas of the epithelial system in vivo. In particular, a multicellular, layered, microfluidic culture is described, allowing for interactions between lamina propria-derived cells and the associated tissue specific epithelial cells and endothelial cells. This in vitro micr…
Who is the assignee on this patent?
Emulate Inc
What technology area does this patent fall under?
Primary CPC classification C12M23/16. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jul 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 10 related publications on this page (citations in our corpus or others sharing the same primary CPC).